SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Prospector who wrote (2)	5/21/1998 10:26:00 AM
From: Profiteer	Read Replies (3) of 5402

Prospector: your use of metaphors can be confusing at times, but amusing. Thanks for sharing the conversation you had with Sanguine. I would think the contract you are referring to will play a major role in funding their commitment with Battelle Research to carry out further testing. Was a name mentioned in connection to the proposed contract announcement? The blood substitute that Battelle is testing is composed of perfluoro-decalin molecules, purified water and proprietary, synthetic, fluorinated surfactant to hold the emulsion together. It has great oxygen carrying capacity and SGNC believes that PHER-02 may carry three to four times the oxygen of human blood per unit volume. This may make PHER-02 useful in the treatment of heart attacks, strokes, cancer and other diseases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next